ACADIA PHARMACEUTICALS INC 8-K

What Happened
Acadia Pharmaceuticals Inc. announced its financial results for the three months ended March 31, 2026 via a press release dated May 6, 2026. The company filed an 8‑K (Item 2.02) to furnish that press release (Exhibit 99.1) with the SEC.

Key Details

• Filing date: May 6, 2026 (8‑K filed to furnish press release).
• Period reported: three months ended March 31, 2026 (Q1 2026).
• Exhibit furnished: Press Release dated May 6, 2026 (Exhibit 99.1).
• Report signed by: Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer.

Why It Matters
Quarterly results provide updated information on Acadia’s recent financial performance—important for investors tracking earnings, revenue, cash flow, or guidance changes. This 8‑K furnishes the press release but does not itself include detailed financial line items; investors should read Exhibit 99.1 or the company’s investor materials for the full metrics and management commentary.